Table 1. Sample IDs and groupings by HPV-risk, genotypes and cytology.
| # | Sample ID |
Genotyping Result |
Cytology | HPV Risk |
HPV Status |
Group |
|---|---|---|---|---|---|---|
| 1 | 35 | Negative | LGSIL | Negative | Negative | HPV- |
| 2 | 50 | Negative | ASCUS | Negative | Negative | HPV- |
| 3 | 53** | Negative | HGSIL | Negative | Negative | EXC |
| 4 | 58 | Negative | LGSIL | Negative | Negative | HPV- |
| 5 | 61 | Negative | HGSIL | Negative | Negative | HPV- |
| 6 | 69 | Negative | HGSIL | Negative | Negative | HPV- |
| 7 | 70 | Negative | HGSIL | Negative | Negative | HPV- |
| 8 | 75 | Negative | HGSIL | Negative | Negative | HPV- |
| 9 | 79 | Negative | NSIL | Negative | Negative | HPV- |
| 10 | 16 | 16,66,6 | LGSIL | Both | Positive | HPV+B |
| 11 | 18* | 16,6,53 | HGSIL | Both | Positive | EXC |
| 12 | 21 | 31,33,42,44,74 | HGSIL | Both | Positive | HPV+B |
| 13 | 22 | 16,31,39,45,66,68,44,53,74 | LGSIL | Both | Positive | HPV+B |
| 14 | 25* | 16,33,66,6 | HGSIL | Both | Positive | EXC |
| 15 | 26 | 16,51,56,6,34,44,53,74 | LGSIL | Both | Positive | HPV+B |
| 16 | 27 | 39,74 | LGSIL | Both | Positive | HPV+B |
| 17 | 28 | 54,56 | HGSIL | Both | Positive | HPV+B |
| 18 | 30 | 16,39,52,53,56 | HGSIL | Both | Positive | HPV+B |
| 19 | 31** | 31,52,6,74 | LGSIL | Both | Positive | EXC |
| 20 | 34 | 16,56,74 | HGSIL | Both | Positive | HPV+B |
| 21 | 36 | 18,44,74 | HGSIL | Both | Positive | HPV+B |
| 22 | 47 | 31,33,44 | HGSIL | Both | Positive | HPV+B |
| 23 | 48 | 33,42 | ASCUS | Both | Positive | HPV+B |
| 24 | 49 | 33,42 | HGSIL | Both | Positive | HPV+B |
| 25 | 51 | 51,53 | ASCUS | Both | Positive | HPV+B |
| 26 | 63 | 51,53,66 | HGSIL | Both | Positive | HPV+B |
| 27 | 65 | 54,45,51 | NA | Both | Positive | HPV+B |
| 28 | 66 | 31,6 | HGSIL | Both | Positive | HPV+B |
| 29 | 17 | 16,66 | HGSIL | H-risk | Positive | HPV+H |
| 30 | 19 | 35 | HGSIL | H-risk | Positive | HPV+H |
| 31 | 20 | 66 | LGSIL | H-risk | Positive | HPV+H |
| 32 | 32 | 52 | LGSIL | H-risk | Positive | HPV+H |
| 33 | 33 | 16 | HGSIL | H-risk | Positive | HPV+H |
| 34 | 37 | 31 | LGSIL | H-risk | Positive | HPV+H |
| 35 | 43 | 51 | LGSIL | H-risk | Positive | HPV+H |
| 36 | 44* | 56 | LGSIL | H-risk | Positive | EXC |
| 37 | 56 | 18,35 | ASCUS | H-risk | Positive | HPV+H |
| 38 | 60 | 51,52,66 | LGSIL | H-risk | Positive | HPV+H |
| 39 | 62 | 16 | LGSIL | H-risk | Positive | HPV+H |
| 40 | 68 | 68 | HGSIL | H-risk | Positive | HPV+H |
| 41 | 72** | 45 | HGSIL | H-risk | Positive | EXC |
| 42 | 74** | 31 | NA | H-risk | Positive | EXC |
| 43 | 78** | 52 | ASCUS | H-risk | Positive | EXC |
*—outlier removed from metabolomics analysis;
**—sample did not produce the total ion chromatogram; EXC—samples excluded from the metabolomics analysis.
Cytology categories: NA-undetermined; LGSIL Low-grade squamous intraepithelial lesion, HGSIL high-grade squamous intraepithelial lesion, ASCUS Atypical squamous cells of undetermined significance, and NSIL Negative for squamous intraepithelial lesion.